Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

33 results about "Letrozole" patented technology

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning.

Composition for preventing and treating polycystic ovarian syndrome and application

The invention belongs to the technical field of biological medicine, and particularly relates to a composition for preventing and treating polycystic ovarian syndrome and application, the composition comprises the following active components: tripterygium wilfordii polysaccharide, dendrobium fimbriatum polysaccharide, hericium erinaceus polysaccharide, lycium barbarum polysaccharide and ackermania muciniphila bacterial suspension. A female SD rat model induced by letrozole and a high-glucose and high-fat feed is adopted to prove the application of Ackermania muciniphila in resisting the polycystic ovarian syndrome, the test method is safe and reliable, the test result is accurate, the curative effect is remarkable, and the invention provides a composition capable of inhibiting or improving or treating the polycystic ovarian syndrome. Compared with single oral administration of ackermania muciniphila suspension, the composition provided by the invention has the advantages that the effect is better, the components of the composition are safer, the technical problem that side effects exist when existing chemical synthesis medicines are used for treating the polycystic ovarian syndrome is solved, and the composition has a good application prospect.
Owner:WEIFANG MEDICAL UNIV

Methods and compositions for treating cancer

Disclosed herein is a method of treating ovarian cancer by administering to the subject a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, alone or in combination with a second agent such as letrozole.
Owner:ONCONOVA THERAPEUTICS INC

Application of urofollitropin for injection combined with letrozole in the preparation of a kit for infertility

The present invention relates to the technical field of infertility treatment, and particularly to the application of urofollitropin for injection combined with letrozole in the preparation of a kit for infertility. The present invention for the first time combines urofollitropin for injection and letrozole to prepare soluble microneedles. Specifically, urofollitropin for injection and letrozole are used as drug active ingredients, and the drug active ingredients are loaded in the form of PLGA-chitosan cross-linked microspheres to prepare soluble microneedles. Through verification and analysis, it is found that the soluble microneedles can effectively solve the problem of medication compliance existing in the prior art and can greatly improve the technical effect of traditional treatment methods.
Owner:THE THIRD AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY

Combination therapies for treatment of breast cancer

ActiveTWI943875B
This invention provides a combination therapy comprising a PI3K inhibitor (e.g., epfuliximab), a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant; and a method for treating patients (preferably those with PIC3CA mutations) with hormone receptor-positive and HER2-negative (HR+ / HER2-) locally advanced or metastatic breast cancer, the method comprising administering a therapeutically effective amount of epfuliximab or a pharmaceutically acceptable salt thereof, a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
Owner:GENENTECH INC

Methods and compositions for treating cancer

Disclosed herein is a method of treating endometrial cancer by administering to the subject a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, alone or in combination with a second agent such as letrozole.
Owner:ONCONOVA THERAPEUTICS INC

Method of selecting treatment for cancer patient

The present disclosure relates to novel predictive methods and personalized therapies for treating patients with cancer, such as breast cancer. In particular, the present disclosure relates to methods of treating a patient having cancer by selectively administering a combination of a CDK 4 / 6 inhibitor and letrozole. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful for predicting the likelihood that a patient having a cancer, such as breast cancer, will respond to a combination treatment of a CDK 4 / 6 inhibitor, such as ribociclib and an aromatase inhibitor letrozole.
Owner:NOVARTIS AG

Methods and compositions for treating cancer

Disclosed herein is a method of treating endometrial cancer by administering to a subject a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, alone or in combination with a second agent, such as letrozole. Provided herein are compositions and methods for treating endometrial cancer by administering to a subject in need of treatment a pharmaceutical composition, the pharmaceutical composition comprising a therapeutically effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, in a unit dosage form. In some embodiments, the method further comprises administering a second pharmaceutical composition comprising a therapeutically effective amount of a second compound, e.g., an estrogen blocker, in a unit dosage form.
Owner:オンコノヴァ セラピューティクス インコーポレイテッド

Letrozole-cyclodextrin compound tablet and stability optimization process

The invention relates to a letrozole-cyclodextrin compound as well as a tablet and a stability optimization process thereof, and belongs to the technical field of pharmaceutical preparations. The letrozole-cyclodextrin compound disclosed by the invention is prepared from letrozole, cyclodextrin and a stable solubilizer through a high-temperature wet grinding process and an inclusion process. The invention also provides a tablet prepared from the compound and pharmaceutical auxiliary materials, the problems of poor water solubility and low bioavailability of letrozole are effectively improved, compared with the prior art, the compound is high in encapsulation efficiency and strong in stability, the dissolution rate of the tablet is remarkably improved, and a better pharmaceutical preparation is provided for breast cancer treatment.
Owner:HARBIN MEDICAL UNIVERSITY

Methods and compositions for treating alzheimer's disease

Provided are methods and compositions for treating Alzheimer's disease (AD). Aspects of the present disclosure include methods of treating Alzheimer's disease (AD), the methods comprising administering to a subject having Alzheimer's disease a therapeutically effective amount of irinotecan and letrozole. Aspects of the present disclosure further include pharmaceutical compositions comprising irinotecan, letrozole, and a pharmaceutically acceptable carrier. Use of such compositions for treating Alzheimer's disease (AD) are also provided.
Owner:RGT UNIV OF CALIFORNIA +1

Improved aromatase inhibitor dosing schedules and compositions

Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.
Owner:LAB FARM ROVI SA

Application of rare ginsenoside Rg5 in the preparation of drugs for inhibiting, improving or treating polycystic ovary syndrome

The invention provides an application of rare ginsenoside Rg5 in preparing a drug for inhibiting, improving or treating polycystic ovary syndrome. Experiments have shown that rare ginsenoside Rg5 has a significant effect of promoting the proliferation of polycystic ovary syndrome-like ovarian granulosa cells and inhibiting, improving or treating polycystic ovary syndrome, and can be used to prepare a drug for inhibiting, improving or treating polycystic ovary syndrome and a drug for promoting the proliferation of polycystic ovary syndrome-like ovarian granulosa cells. The invention uses a polycystic ovary syndrome-like human ovarian granulosa cell model induced by oleic acid and androsol to demonstrate the application of rare ginsenoside Rg5 in promoting the proliferation of polycystic ovary syndrome-like ovarian granulosa cells, and uses a female SD rat model induced by letrozole and a high-sugar and high-fat feed to demonstrate the application of rare ginsenoside Rg5 in resisting polycystic ovary syndrome. The test method is safe and reliable, the test result is accurate, the therapeutic effect is significant, and there is no toxic side effect. The invention belongs to the field of medical technology.
Owner:WEIFANG MEDICAL UNIV

Use of letrozole in the preparation of drugs for treating lymphoma

This invention discloses the use of letrozole or its pharmaceutically acceptable salts, solvates, or hydrates in the preparation of medicaments for treating lymphoma. Experimental verification has shown that letrozole or its pharmaceutically acceptable salts, solvates, or hydrates can be used to treat lymphoma, particularly diffuse large B-cell lymphoma with c-MYC rearrangements.
Owner:SECOND MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Application of fructus psoraleae extract and active ingredient psoralen of fructus psoraleae extract in preparation of medicine for treating polycystic ovarian syndrome

The invention relates to the field of biomedicine, in particular to application of a fructus psoraleae extract and an active ingredient psoralen thereof in preparation of a medicine for treating polycystic ovarian syndrome. According to the invention, a letrozole-induced polycystic ovarian syndrome mouse disease model is constructed, and experiments such as estrus cycle detection, open field experiment, sex hormone ELISA detection and the like are carried out. Experimental results show that the fructus psoraleae extract and the fructus psoraleae can effectively relieve and correct a PCOS mouse estrus cycle disorder state, improve ovarian polycystic change, increase the number of corpus luteum, reduce the number of atresia follicles and cystic follicles, and recover normal ovarian functions and reproductive endocrine disorder. The invention provides a new thought for research and development of medicines for treating polycystic ovarian syndrome.
Owner:GANNAN MEDICAL UNIV

Application of maca in preparation of medicine for improving polycystic ovarian syndrome

The invention discloses application of maca in preparation of a medicine for improving polycystic ovarian syndrome, and belongs to the field of biological medicine. According to the present invention, letrozole and high-fat feed are adopted to induce and construct a polycystic ovarian syndrome mouse model, and experiments such as estrus cycle detection, ovary and uterus morphology observation, sex hormone detection, blood sugar level detection and the like are performed; results show that the maca can effectively improve the rhythm disorder of the estrus cycle, the polycystic ovarian form and the uterine form of the polycystic ovarian syndrome model mouse, correct the reproductive endocrine disorder, recover the normal ovarian ovulation function and relieve the insulin resistance symptom of the polycystic ovarian syndrome model mouse. A new thought is provided for research and development of medicines for treating the polycystic ovarian syndrome, and maca is expected to become a potential candidate medicine for treating the polycystic ovarian syndrome and has a wide application prospect.
Owner:GANNAN MEDICAL UNIV

A large-scale breeding method for all-female large yellow croaker

The present invention relates to the technical field of fish breeding and discloses a large-scale breeding method for all-female large yellow croaker. The present invention provides a method for inducing sex reversal in genetically female large yellow croaker by feeding them a formula feed containing letrozole, producing pseudo-male fish. The pseudo-male fish are then identified through live marking and screening. The pseudo-male fish are then fertilized with genetically female large yellow croaker to produce all-female fish, thereby achieving large-scale breeding of all-female seedlings. The method has high induction efficiency for inducing female large yellow croaker to pseudo-male fish, does not use androgens, and is safe and simple.
Owner:MARINE FISHERIES RES INST OF ZHEJIANG

A synthetic method for anti-breast cancer drug letrozole analogues

The invention discloses a method for synthesizing an anti-breast cancer drug letrozole analog. The method uses commercial 4-chlorobenzaldehyde as a starting material, and undergoes a multi-component free radical coupling of [1.1.1] propellerane with 4-chlorobenzaldehyde and 1,3-dioxolane under ultraviolet light irradiation, and then hydrolyzes the product under dilute hydrochloric acid to obtain an intermediate bicyclo[1.1.1]pentane (BCP) aldehyde. The aldehyde is then converted into a cyano group, and the hydroxyl group is chlorinated under thionyl chloride conditions. The product is then reacted with 1,2,4-triazole in the presence of potassium carbonate through a one-step S- N The second reaction yields a benzyl triazole compound containing a BCP structure, which is then subjected to a one-step, photopromoted nickel-catalyzed cyanation of the aryl chloride to yield the target product. The present invention utilizes inexpensive raw materials, a short synthesis process, and mild conditions. The resulting target product is expected to become a novel anti-breast cancer drug with enhanced pharmacological activity.
Owner:SHAANXI NORMAL UNIV

Improved aromatase inhibitor dosing schedules and compositions

PendingAU2024421649A1DiseaseAromatase inhibitor
Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.
Owner:LAB FARM ROVI SA

Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4 / 6 inhibitors

ActiveUS12685719B2ToremifeneEverolimus
This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.
Owner:UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

A composition for treating infertility caused by polycystic ovary syndrome and use thereof

The application provides a composition for treating infertility caused by polycystic ovary syndrome, which is composed of traditional Chinese medicines and western medicines. The traditional Chinese medicines are prepared from raw medicinal materials in the following proportions by weight: 5-13 parts of donkey-hide gelatin, 9-21 parts of prepared rehmannia, 5-13 parts of angelica, 9-21 parts of semen cuscutae, 5-13 parts of ligustrum lucidum ait, 5-13 parts of codonopsis pilosula, 5-13 parts of white atractylodes rhizome, 9-21 parts of polygonatum, 5-13 parts of rhizoma caryophylli, and 5-13 parts of chuanxiong. The western medicine is letrozole. The application also provides the use of the composition. The advantage of the application is that clinical and animal experiments have confirmed that the effect of letrozole combined with the traditional Chinese medicine decoction of the application on treating infertility caused by polycystic ovary syndrome is better, and the ovulation rate and pregnancy rate are significantly improved, so the application is worth promoting.
Owner:SHANGHAI FIRST MATERNITY & INFANT HOSPITAL

Combination therapies for treatment of breast cancer

Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+ / HER2−) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
Owner:GENENTECH INC

Use of cyp2a6 genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy for breast cancer

The application provides use of CYP2A6 genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy for breast cancer, patients with CYP2A6 intermediate / slow metabolism type are more likely to achieve pCR than patients with normal metabolism type, CYP2A6 rs61663607 T>C TT type is more likely to achieve pCR than TC and CC types, in patients with neoadjuvant chemotherapy combined with or without letrozole, CYP2A6 rs7250713 G>C CC type is more likely to achieve pCR than CC and CG types. The application also provides use of CYP2A6 genotype in preparation of a reagent for diagnosing and predicting the efficacy of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy for breast cancer. The application is used for auxiliary diagnosis of the efficacy of neoadjuvant chemotherapy combined with or without letrozole treatment for early hormone receptor positive breast cancer patients receiving neoadjuvant therapy and surgery.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Crystal form iii of letrozole solid substance, preparation method and pharmaceutical composition and use thereof

The application discloses a crystal III type substance of letrozole compound (chemical name: 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole, English name: Letrozole), a preparation method of the crystal III type substance, and a pharmaceutical composition and application of the crystal III type substance. Specifically, the application discloses a crystal III type solid substance state of the letrozole compound, a preparation method of a crystal III type solid substance sample, and application of the letrozole crystal substance as an active ingredient in preparation of an anti-hormone antitumor drug.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

Medicine for treating infertility and preparation method thereof

The invention belongs to the field of pharmaceutical preparations, and provides a medicine for treating infertility and a preparation method thereof. According to the invention, a biphase controlled release tablet design is adopted, a quick release layer contains 0.8-2.0 wt% of polyethylene glycol-hemisuccinic acid choline salt as an ion pair auxiliary release agent, and the polyethylene glycol-hemisuccinic acid choline salt has accurately regulated number-average molecular weight of 1000-2000, terminal group substitution degree of 1.8-2.0, neutralization degree of more than or equal to 95% and low acid value of less than or equal to 5.0 mg KOH / g; the surfaces of letrozole particles are micro-coated with a fluidized bed to form 1.0-1.5 wt% of a uniform weight-increasing coating layer, and diffusion control of 15-45 wt% of hydroxypropyl methylcellulose in a slow-release layer is combined, so that double-time-window stable drug release of 45-60% of accumulated release within 2 hours and 85-95% of accumulated release within 24 hours is realized; triple contradictions between tablet densification and double-time window release channel maintenance, micro-coating process window and initial release consistency, low water-containing stability of a formula and ion pair assisted release hydration requirements are solved, and the tablet is suitable for treating ovulation disorder related infertility and has wide clinical application value.
Owner:NANJING COMTRUE MEDICAL TECH CO LTD

Method for promoting male development and mature gamete generation of epinephelus coioides

InactiveCN118947592AImprove sexual maturity rateIncreased sexual maturity rateAnimal reproductionClimate change adaptationAnimal scienceBroodstock
The invention provides a method for promoting male development of epinephelus coioides and producing mature gametes, which comprises the following steps: selecting epinephelus coioides and epinephelus fuscoguttatus of 4-7 ages as parent fishes, and temporarily culturing in a specific factory cement culture pond environment. In the aspect of medicine preparation, the optimal mass ratio of ketotestosterone to letrozole to algal polysaccharide is determined, and the ketotestosterone, the letrozole and the algal polysaccharide are implanted after special treatment. A clear standard is provided for judging the maturity of the parent fish, and the seminal fluid is collected by adopting a scientific method and is properly stored. And an artificial insemination link: obtaining eggs from the female fish, then adopting a dry-type insemination method, and carrying out micro-flowing water incubation on the fertilized eggs under proper conditions. The method provides an effective way for the breeding of the epinephelus coioides, has important significance for the development of the epinephelus coioides breeding industry, is expected to improve the breeding efficiency and quality of the epinephelus coioides, further meets the market requirements, and also provides valuable reference for the research of fish reproductive biology.
Owner:HAINAN BLUE GRAIN TECH CO LTD

Method of selecting treatment for cancer patient

The present disclosure relates to novel predictive methods and personalized therapies for treating patients with cancer, such as breast cancer. In particular, the present disclosure relates to methods of treating a patient having cancer by selectively administering a combination of a CDK 4 / 6 inhibitor and letrozole. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful for predicting the likelihood that a patient having a cancer, such as breast cancer, will respond to a combination treatment of a CDK 4 / 6 inhibitor, such as ribociclib and an aromatase inhibitor letrozole.
Owner:NOVARTIS AG

Therapeutic use of aromatase inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of malignancies

Methods for treating gliomas, such as glioblastoma, including administering an aromatase inhibitor, such as letrozole, to a subject suffering from a glioma. The method may further include administering the aromatase inhibitor in combination with a poly-ADP ribose polymerase inhibitor, such as olaparib, pamiparib, veliparib or niraparib.
Owner:UNIVERSITY OF CINCINNATI

An induction method for efficient sex reversal of adult female Nibea albiflora

The invention discloses an efficient inducing method for sex reversal of adult female yellow croaker, belonging to the technical field of female fish sex reversal. The invention specifically relates to a method for ablating oocytes of adult female yellow croaker using busulfan, and then feeding the treated adult female yellow croaker with a compound feed containing an aromatase inhibitor for 6-12 months to obtain adult yellow croaker with successful sex reversal. The aromatase inhibitor is letrozole, and busulfan can be used in combination with a pyrimidine compound or a pyrimidine-based chalcone. Thus, the method has the following beneficial effects: a high survival rate of the adult yellow croaker, which is above 90%, and a high sex reversal success rate, which is above 70%.
Owner:MARINE FISHERIES RES INST OF ZHEJIANG

A method and application of rapid and large-scale production of all-female Yellow River carp based on differentiated ovaries

The present invention belongs to the technical field of genetic breeding of aquatic animals, and specifically relates to a method and application for rapid large-scale production of all-female Yellow River carp based on differentiated ovaries. The present invention feeds a feed containing letrozole to 120-day-old female carp whose gonads have differentiated into second-stage ovaries, and can obtain pseudo-male carp that can squeeze out semen within 3 months, without considering the difficulty of the key sensitive period of sex determination required by the traditional artificial induced sex reversal technology, and the survival rate is 100%, and the drug tolerance is strong; and the artificial induced sex reversal technology used is efficient, fast, simple, easy, and can continuously produce all-female carp on a large scale, and the obtained XX pseudo-male carp can squeeze out functional semen at the age of 7 months, and can be used for large-scale production of all-female carp in the second year breeding season. The method is used to treat 3-month-old XX female carp obtained by normal fertilization, and all female carp can be sex-reversed to XX pseudo-male carp, and all of them squeeze out functional semen in the second year breeding season.
Owner:GUANGDONG OCEAN UNIVERSITY +1